Treatment following ibrutinib or idelalisib discontinuation
| n = 114 . | n . | Percentage (%) . |
|---|---|---|
| Idelalisib-based | 25 | 21.9 |
| Ibrutinib-based | 19 | 16.7 |
| BCL2-I | 16 | 14.0 |
| Other | 10 | 8.7 |
| Fludarabine/Bendamustine CIT | 9 | 7.9 |
| R-anthracycline-based | 9 | 7.9 |
| Cellular-based therapy | 8 | 7.0 |
| Rituximab | 7 | 6.1 |
| Obinutuzumab | 5 | 4.4 |
| Syk-inhibitor | 2 | 1.8 |
| Ofatumumab | 2 | 1.8 |
| Immunomodulatory derivatives–based | 2 | 1.8 |
| n = 114 . | n . | Percentage (%) . |
|---|---|---|
| Idelalisib-based | 25 | 21.9 |
| Ibrutinib-based | 19 | 16.7 |
| BCL2-I | 16 | 14.0 |
| Other | 10 | 8.7 |
| Fludarabine/Bendamustine CIT | 9 | 7.9 |
| R-anthracycline-based | 9 | 7.9 |
| Cellular-based therapy | 8 | 7.0 |
| Rituximab | 7 | 6.1 |
| Obinutuzumab | 5 | 4.4 |
| Syk-inhibitor | 2 | 1.8 |
| Ofatumumab | 2 | 1.8 |
| Immunomodulatory derivatives–based | 2 | 1.8 |